indomethacin has been researched along with Renal Insufficiency in 20 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
Renal Insufficiency: Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Long-term indomethacin treatment during pregnancy may lead to the development of renal failure and irreversible renal damage with cystic dilatation of developing nephrons in an exposed fetus." | 7.69 | Persistent anuria, neonatal death, and renal microcystic lesions after prenatal exposure to indomethacin. ( Bavoux, F; Carlus, C; Delezoide, AL; Gubler, MC; Narcy, F; van der Heijden, BJ, 1994) |
| "Eighteen pregnant women were given indomethacin during the year 1989 for treatment of premature labor (n = 16) or polyhydramnios (n = 2)." | 7.68 | [Maternal and neonatal effects of indomethacin administrated during pregnancy. Apropos of 18 cases]. ( Bavoux, F; Blot, P; Boissinot, C; Guillonneau, M; Hartmann, JF; Jacqz-Aigrain, E, 1993) |
| " Oral ibuprofen is associated with lower instance of necrotizing enterocolitis." | 4.95 | Patent Ductus Arteriosus in the Preterm Infant: Diagnostic and Treatment Options. ( Keim-Malpass, J; Prescott, S, 2017) |
| " Up to the present day, several cases of severe and sometimes irreversible renal insufficiency have been described in neonates exposed to indomethacin prenatally or in the first days of life for treatment of patent ductus arteriosus (PDA)." | 4.81 | NSAID-induced nephrotoxicity from the fetus to the child. ( Cuzzolin, L; Dal Cerè, M; Fanos, V, 2001) |
| "To compare the incidence of medical closure of patent ductus arteriosus (PDA) and adverse events (acute renal dysfunction, necrotizing enterocolitis, spontaneous intestinal perforation, and gastrointestinal bleeding) between preterm infants who received indomethacin and ibuprofen for the treatment of PDA." | 3.79 | Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants. ( Bali, V; Harabor, A; Kamaluddeen, M; Sivanandan, S; Soraisham, AS, 2013) |
| "Long-term indomethacin treatment during pregnancy may lead to the development of renal failure and irreversible renal damage with cystic dilatation of developing nephrons in an exposed fetus." | 3.69 | Persistent anuria, neonatal death, and renal microcystic lesions after prenatal exposure to indomethacin. ( Bavoux, F; Carlus, C; Delezoide, AL; Gubler, MC; Narcy, F; van der Heijden, BJ, 1994) |
| "Three cases of neonatal renal insufficiency in very low birthweight (VLBW) infants following repeated antenatal administration of indomethacin to prevent premature labor are reported." | 3.69 | Renal impairment in very low birthweight infants following antenatal indomethacin administration. ( Ichijo, M; Kawaguchi, C; Nakagawa, Y; Nakajima, M; Nishikubo, T; Takahashi, Y; Yoshioka, A, 1994) |
| "Indomethacin has been shown to have adverse effects on renal function in patients with well-compensated alcoholic cirrhosis." | 3.69 | The effect of misoprostol on indomethacin-induced renal dysfunction in well-compensated cirrhosis. ( Dudley, F; Hsu, P; Massie, D; Wong, F, 1995) |
| "Eighteen pregnant women were given indomethacin during the year 1989 for treatment of premature labor (n = 16) or polyhydramnios (n = 2)." | 3.68 | [Maternal and neonatal effects of indomethacin administrated during pregnancy. Apropos of 18 cases]. ( Bavoux, F; Blot, P; Boissinot, C; Guillonneau, M; Hartmann, JF; Jacqz-Aigrain, E, 1993) |
| "Increasing indomethacin concentrations above the levels achieved with a conventional dosing regimen had little effect on the rate of PDA closure but was associated with higher rates of moderate/severe ROP and renal compromise." | 2.73 | Increased indomethacin dosing for persistent patent ductus arteriosus in preterm infants: a multicenter, randomized, controlled trial. ( Buchh, B; Chorne, N; Clyman, R; Ewig, A; Fields, S; Ianus, V; Jegatheesan, P; Lin, E; Milstein, J; Moon-Grady, A; Padbury, J; Schreiber, M; Tacy, T; Yoon, G, 2008) |
| "Ibuprofen appears to be a better choice for PDA closure, with a better side effect profile and efficacy that equals that of indomethacin." | 2.53 | Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration. ( Agarwal, R; Sivanandan, S, 2016) |
| "Indomethacin is a non-steroidal anti-inflammatory drug that is a potent inhibitor of prostaglandin E(2) synthesis." | 2.49 | Clinical pharmacology of indomethacin in preterm infants: implications in patent ductus arteriosus closure. ( Pacifici, GM, 2013) |
| "Indomethacin therapy for closure of patent ductus arteriosus frequently causes oliguria, and occasionally more serious renal dysfunction." | 2.41 | Dopamine versus no treatment to prevent renal dysfunction in indomethacin-treated preterm newborn infants. ( Barrington, K; Brion, LP, 2002) |
| "The symptomatic patent ductus arteriosus (sPDA) is common in extremely premature infants (EPI)." | 1.46 | [Digestive and Kidney Complications by indomethacin and ibuprofen in extreme preterm infants with patent ductus arteriosus]. ( Lavín, P; López, M; Miranda, J; Rincón, Y; Salas, R, 2017) |
| "Kidney failure is associated with changes in renal vascular responses to angiotensin (Ang) II." | 1.31 | Angiotensin II type AT(2) receptor mRNA expression and renal vasodilatation are increased in renal failure. ( Bautista, R; Escalante, B; Hernández, J; Oyekan, A; Sánchez, A, 2001) |
| "Kidney failure is the common end of hypertension and renal diseases." | 1.30 | Effect of cyclooxygenase-2 inhibition on renal function after renal ablation. ( Escalante, B; Ferreri, NR; Salgado, LM; Sanchez, PL, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (35.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Salas, R | 1 |
| Lavín, P | 1 |
| Rincón, Y | 1 |
| Miranda, J | 1 |
| López, M | 1 |
| Pacifici, GM | 1 |
| Waeckel, L | 1 |
| Bertin, F | 1 |
| Clavreul, N | 1 |
| Damery, T | 1 |
| Köhler, R | 1 |
| Paysant, J | 1 |
| Sansilvestri-Morel, P | 1 |
| Simonet, S | 1 |
| Vayssettes-Courchay, C | 1 |
| Wulff, H | 1 |
| Verbeuren, TJ | 1 |
| Félétou, M | 1 |
| Sivanandan, S | 2 |
| Agarwal, R | 1 |
| Prescott, S | 1 |
| Keim-Malpass, J | 1 |
| Jegatheesan, P | 1 |
| Ianus, V | 1 |
| Buchh, B | 1 |
| Yoon, G | 1 |
| Chorne, N | 1 |
| Ewig, A | 1 |
| Lin, E | 1 |
| Fields, S | 1 |
| Moon-Grady, A | 1 |
| Tacy, T | 1 |
| Milstein, J | 1 |
| Schreiber, M | 1 |
| Padbury, J | 1 |
| Clyman, R | 1 |
| Heo, MJ | 1 |
| Lee, OS | 1 |
| Lim, SC | 1 |
| Bali, V | 1 |
| Soraisham, AS | 1 |
| Harabor, A | 1 |
| Kamaluddeen, M | 1 |
| Barrington, K | 1 |
| Brion, LP | 1 |
| Kömhoff, M | 1 |
| Tekesin, I | 1 |
| Peters, M | 1 |
| Leonhard, A | 1 |
| Seyberth, HW | 1 |
| van der Heijden, BJ | 1 |
| Carlus, C | 1 |
| Narcy, F | 1 |
| Bavoux, F | 3 |
| Delezoide, AL | 1 |
| Gubler, MC | 1 |
| Nishikubo, T | 1 |
| Takahashi, Y | 1 |
| Nakagawa, Y | 1 |
| Kawaguchi, C | 1 |
| Nakajima, M | 1 |
| Ichijo, M | 1 |
| Yoshioka, A | 1 |
| Agnoli, GC | 1 |
| Borgatti, R | 1 |
| Cacciari, M | 1 |
| Ikonomu, E | 1 |
| Lenzi, P | 1 |
| Marinelli, M | 1 |
| Jacqz-Aigrain, E | 1 |
| Guillonneau, M | 1 |
| Boissinot, C | 1 |
| Hartmann, JF | 1 |
| Blot, P | 1 |
| Wong, F | 1 |
| Massie, D | 1 |
| Hsu, P | 1 |
| Dudley, F | 1 |
| Sanchez, PL | 1 |
| Salgado, LM | 1 |
| Ferreri, NR | 1 |
| Escalante, B | 2 |
| Cuzzolin, L | 1 |
| Dal Cerè, M | 1 |
| Fanos, V | 1 |
| Bautista, R | 1 |
| Sánchez, A | 1 |
| Hernández, J | 1 |
| Oyekan, A | 1 |
| Monasterolo, LA | 1 |
| Ochoa, JE | 1 |
| Elías, MM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Combination of Acetaminophen and Ibuprofen in the Management of Patent Ductus Arteriosus in Premature Infants: A Pilot Study[NCT03103022] | Phase 1 | 20 participants (Actual) | Interventional | 2017-06-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for indomethacin and Renal Insufficiency
| Article | Year |
|---|---|
Clinical pharmacology of indomethacin in preterm infants: implications in patent ductus arteriosus closure.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Blood Flow Velocity; Ductus Arteriosus, Patent | 2013 |
Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Decision Making; Drug Administra | 2016 |
Patent Ductus Arteriosus in the Preterm Infant: Diagnostic and Treatment Options.
Topics: Biomarkers; Cardiac Catheterization; Conservative Treatment; Cyclooxygenase Inhibitors; Ductus Arter | 2017 |
Dopamine versus no treatment to prevent renal dysfunction in indomethacin-treated preterm newborn infants.
Topics: Cardiovascular Agents; Dopamine; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; I | 2002 |
NSAID-induced nephrotoxicity from the fetus to the child.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Ductus Arteriosus, Patent; Female; | 2001 |
[Fetal toxicity of non-steroidal anti-inflammatory agents].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Fetal Diseases; Heart Failure; Humans; Indomethacin | 1992 |
1 trial available for indomethacin and Renal Insufficiency
| Article | Year |
|---|---|
Increased indomethacin dosing for persistent patent ductus arteriosus in preterm infants: a multicenter, randomized, controlled trial.
Topics: Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Echocardiogr | 2008 |
13 other studies available for indomethacin and Renal Insufficiency
| Article | Year |
|---|---|
[Digestive and Kidney Complications by indomethacin and ibuprofen in extreme preterm infants with patent ductus arteriosus].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Enterocolitis; Female; Humans; I | 2017 |
Preserved regulation of renal perfusion pressure by small and intermediate conductance KCa channels in hypertensive mice with or without renal failure.
Topics: Angiotensinogen; Animals; Endothelium, Vascular; Female; Humans; Hypertension, Renovascular; Indomet | 2015 |
Comparative evaluation for the use of oral ibuprofen and intravenous indomethacin in Korean infants with patent ductus.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Comorbidity; Ductus Arteriosus, Paten | 2012 |
Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Fema | 2013 |
Perinatal management of a preterm neonate affected by hyperprostaglandin E2 syndrome (HPS).
Topics: Bartter Syndrome; Cyclooxygenase Inhibitors; Female; Humans; Indomethacin; Infant, Newborn; Perinata | 2005 |
Persistent anuria, neonatal death, and renal microcystic lesions after prenatal exposure to indomethacin.
Topics: Adult; Anuria; Dilatation, Pathologic; Female; Fetal Death; Humans; Immunohistochemistry; Indomethac | 1994 |
Renal impairment in very low birthweight infants following antenatal indomethacin administration.
Topics: Adult; Female; Humans; Indomethacin; Infant, Low Birth Weight; Infant, Newborn; Male; Maternal-Fetal | 1994 |
Effects of angiotensin-converting enzyme inhibition on renal dysfunction induced by moderate potassium depletion in healthy women.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Enalapril; Female; Humans; Indomethacin; Kidney Fun | 1994 |
[Maternal and neonatal effects of indomethacin administrated during pregnancy. Apropos of 18 cases].
Topics: Adult; Female; Humans; Indomethacin; Infant, Newborn; Male; Obstetric Labor, Premature; Polyhydramni | 1993 |
The effect of misoprostol on indomethacin-induced renal dysfunction in well-compensated cirrhosis.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Drug Interactions; Drug Therapy | 1995 |
Effect of cyclooxygenase-2 inhibition on renal function after renal ablation.
Topics: Animals; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; | 1999 |
Angiotensin II type AT(2) receptor mRNA expression and renal vasodilatation are increased in renal failure.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 5,8,11,14-Eicosatetraynoic Acid; | 2001 |
Rat renal function four days after bile-duct ligation: effects of indomethacin and vasoactive agents.
Topics: Animals; Bile Ducts; Cyclooxygenase Inhibitors; Disease Models, Animal; Glomerular Filtration Rate; | 2002 |